For example, other preclinical studies have previously demonstrated siRNA-mediated protection of the heart following myocardial infarction or ischemia/reperfusion injury by targeting genes such as Nox2 and HIF-1alpha-prolyl-4 hydroxylase-2, although non-invasive targeted delivery approaches were not employed [32, 33]. The gene discussed is CYBB; the disease is myocardial infarction.